PTCT Live signals | Maximize Profits with Getagraph.com

BUY 103232 min ago

@ $25.11

Issued: 14 Feb 2024 @ 15:41

Return: 1.51%

Previous signal: Feb 13 - 15:43

Previous signal: Sell

Return: 3.95 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...

Stats
Today's Volume	860 659
Average Volume	898 040
Market Cap	1.95B
EPS	$0 ( 2024-04-25 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-3.05
ATR14	$0.0400 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Klein Matthew B.	Sell	3 361	Common Stock
2024-04-17	Pauwels Eric	Sell	787	Common Stock
2024-04-17	Klein Matthew B.	Sell	1 307	Common Stock
2024-04-02	Golden Lee Scott	Sell	526	Common Stock
2024-02-15	Utter Christine Marie	Buy	2 900	Common Stock

INSIDER POWER
73.34
Last 98 transactions
Buy: 1 039 114 \| Sell: 204 439

Volume Correlation

Long: 0.12 (neutral)

Short: -0.59 (weak negative)

Signal:(53.539) Neutral

PTC Therapeutics Inc Correlation

10 Most Positive Correlations
MOSY	0.894
ATCX	0.831
IKNX	0.824
SPKE	0.821
ICON	0.82
SYKE	0.811
APOP	0.811
NTES	0.807
APR	0.805
UBX	0.804

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

PTC Therapeutics Inc Correlation - Currency/Commodity

0.11
( neutral )

0.24
( neutral )

0.00
( neutral )

-0.32
( neutral )

0.36
( neutral )

0.48
( neutral )

PTC Therapeutics Inc Financials

Annual	2023
Revenue:	$937.82M
Gross Profit:	$649.70M (69.28 %)
EPS:	$-8.37

FY	2023
Revenue:	$937.82M
Gross Profit:	$649.70M (69.28 %)
EPS:	$-8.37

FY	2022
Revenue:	$698.80M
Gross Profit:	$654.12M (93.61 %)
EPS:	$-7.79

FY	2021
Revenue:	$538.59M
Gross Profit:	$506.27M (94.00 %)
EPS:	$-7.26

Financial Reports:

No articles found.

PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.